Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor  by Seth, Pankaj et al.
Expression pattern of the type 1 sigma receptor in the brain and identity
of critical anionic amino acid residues in the ligand-binding domain of
the receptor
Pankaj Seth a, Malliga E. Ganapathy b, Simon J. Conway c, Christy D. Bridges a,
Sylvia B. Smith d, Pierre Casellas e, Vadivel Ganapathy a;*
a Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA
b Department of Medicine, Medical College of Georgia, Augusta, GA 30912, USA
c Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
d Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta, GA 30912, USA
e Sano¢, Montpellier Cedex, France
Received 2 October 2000; received in revised form 27 April 2001; accepted 17 May 2001
Abstract
The type 1 c receptor (cR1) has been shown to participate in a variety of functions in the central nervous system. To
identify the specific regions of the brain that are involved in cR1 function, we analyzed the expression pattern of the receptor
mRNA in the mouse brain by in situ hybridization. cR1 mRNA was detectable primarily in the cerebral cortex,
hippocampus, and Purkinje cells of cerebellum. To identify the critical anionic amino acid residues in the ligand-binding
domain of cR1, we employed two different approaches: chemical modification of anionic amino acid residues and site-
directed mutagenesis. Chemical modification of anionic amino acids in cR1 with 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide reduced the ligand-binding activity markedly. Since it is known that a splice variant of this receptor which lacks exon
3 does not have the ability to bind c ligands, the ligand-binding domain with its critical anionic amino acid residues is likely
to be present in or around the region coded by exon 3. Therefore, each of the anionic amino acids in this region was mutated
individually and the influence of each mutation on ligand binding was assessed. These studies have identified two anionic
amino acids, D126 and E172, that are obligatory for ligand binding. Even though the ligand-binding function was abolished
by these two mutations, the expression of these mutants was normal at the protein level. These results show that cR1 is
expressed at high levels in specific areas of the brain that are involved in memory, emotion and motor functions. The results
also provide important information on the chemical nature of the ligand-binding site of cR1 that may be of use in the design
of cR1-specific ligands with potential for modulation of cR1-related brain functions. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
c receptors, which interact with several psychoac-
tive agents such as haloperidol, phencyclidine, neuro-
steroids, benzomorphans and cocaine, are de¢ned as
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non-opiate and non-phencyclidine binding sites [1^3].
These binding sites have been identi¢ed in the brain
as well as in a variety of other organs [3]. Based on
the ligand-binding characteristics and biochemical
features, the c ligand binding sites fall into several
subtypes [4]. Of these di¡erent subtypes, the type 1 c
receptor (cR1) represents the best characterized sub-
type at the functional and structural level. Autora-
diographic studies with subtype-speci¢c radiolabeled
ligands have shown that cR1 is expressed at high
levels in speci¢c regions of the brain, primarily in
those areas that are involved in motor, sensory,
and endocrine functions, and in emotion and mem-
ory [5^8]. This subtype has been shown to play vital
roles in learning and memory in animal models of
amnesia [9], in cocaine-induced behavioral changes
[10,11], and in opiate-induced analgesia [12,13]. In
the periphery, cR1 is expressed in the placenta, liver,
immune cells, gastrointestinal tract, and steroid-pro-
ducing organs [1^3,14]. Progesterone is believed to be
one of the endogenous ligands to cR1 [15]. Since
several cR1 ligands are known to be immunosup-
pressive [16], it has been speculated that progester-
one, by acting as a pregnancy-speci¢c ligand to cR1,
might provide at least one of the mechanisms for the
maternal tolerance of the fetal/placental allograft
[17]. cR1 has been shown to be involved in the mod-
ulation of several second messenger systems [2,3]. Of
these, the role of the receptor in Ca2 signaling has
received much attention in recent years [18^22]. The
interaction between cR1 and Ca2 signaling is sup-
ported by the ¢ndings that the receptor is located in
close proximity to the IP3 receptor in the endoplas-
mic reticulum [23].
Until recently, studies involving the function and
distribution of c receptors have been carried out us-
ing ligands that are supposedly speci¢c for di¡erent
subtypes of the receptor. Since many of these ligands
also interact with other receptors in addition to
c receptor subtypes, it has been di⁄cult to obtain a
direct correlation between the ligands’ pharmacolog-
ical actions and their binding to speci¢c c receptor
subtypes. Consequently, despite the large volume of
information available on the pharmacology of a
number of c ligands, the exact roles of di¡erent
c receptor subtypes have remained elusive. Further-
more, there was no information available until re-
cently on the molecular identity of any of these re-
ceptor subtypes and this has also slowed the progress
in de¢ning the structural and functional features of
these receptors. However, currently there is a re-
newed interest in c receptors and their physiological
functions and pharmacological and therapeutic po-
tential because of the recent success in the cloning
and molecular characterization of one of the c re-
ceptor subtypes. cR1 was ¢rst cloned from the guin-
ea pig liver [24]. Subsequently, we and others have
cloned the human, rat, and mouse homologues [25^
29]. Interestingly, the cloned cR1 exhibits no signi¢-
cant homology to any of the mammalian proteins
thus far cloned. However, this receptor is signi¢-
cantly homologous to a sterol metabolizing enzyme
in yeast [24]. This yeast protein is a C8-C7 isomerase
involved in the ergosterol biosynthetic pathway.
However, a mammalian C8-C7 isomerase has been
recently cloned [30,31], but surprisingly this protein
shows no structural similarity to either the yeast
C8-C7 isomerase or mammalian cR1.
With the current availability of molecular tools
such as the cDNA probes and antibodies speci¢c to
cR1, signi¢cant developments have occurred recently
in de¢ning the structural and functional features of
this receptor. With the cloned cR1, we have demon-
strated unequivocally that progesterone functions as
a ligand to this receptor [17]. Use of antisense ap-
proaches has demonstrated that cR1 plays a signi¢-
cant role in opiate-induced analgesia [28]. Studies
with cR1-speci¢c antibodies have established that
cR1 is a membrane-associated protein present in in-
tracellular organelles [32] and that the receptor is
involved in protein^protein interaction with the
type 3 IP3 receptor and ankyrin B regulating Ca2
signaling [33]. There is also evidence for cR1 trans-
location from intracellular sites to plasma membrane
as a result of ligand binding [34], suggesting that
there may be proteins in the plasma membrane, not
yet identi¢ed, that might be targets for cR1 for pro-
tein^protein interaction.
The present study was undertaken for two pur-
poses, ¢rst to assess the expression pattern of cR1
in the brain by in situ hybridization and second to
identify the anionic amino acid residues that play an
essential functional role in the ligand-binding domain
of the receptor. The distribution of cR1 in the brain
has been investigated so far only with ligand-binding
assays. Since there is a signi¢cant degree of overlap
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in ligand speci¢city among di¡erent subtypes of
c receptor, the assessment of the distribution of cR1
mRNA in the brain might provide a more reliable
approach to determine the speci¢c areas of the brain
that express the receptor. The second aim was based
on our recent ¢ndings that a splice variant of cR1
that lacks 31 amino acids coded by exon 3 has no
detectable ligand-binding activity [17]. These ¢ndings
suggest that the ligand-binding domain is likely to be
present in or around the region coded by exon 3.
Since most of the c ligands are positively charged,
we hypothesized that anionic amino acid residues
located in the putative ligand-binding domain may
play a role in the interaction of the receptor with
the ligands.
2. Materials and methods
2.1. Materials
[3H]Haloperidol and (+)-[3H]pentazocine were
purchased from NEN Life Science Products (Boston,
MA, USA). Lipofectin and media and chemicals for
cell culture were purchased from Life-Technologies
(Rockville, MD, USA).
2.2. Preparation of JAR cell crude membranes
The human placental choriocarcinoma cell line
JAR was used to prepare membranes for studies
with native cR1 which is constitutively expressed in
these cells [14]. The cells were lysed using ice-cold
5 mM K2HPO4-KH2PO4 bu¡er, pH 7.5, and the
lysate was homogenized in an Ultra-Turrax Tissue-
mizer. The homogenate was centrifuged at 40 000Ug
for 30 min. The ¢nal membrane pellet was suspended
in 5 mM K2HPO4-KH2PO4 bu¡er, pH 7.5.
2.3. Heterologous expression of cR1s in MCF-7 cells
The vaccinia virus expression system was used to
study the ligand-binding characteristics of the cloned
c receptors. The cR1 cDNAs were expressed hetero-
logously in MCF-7 cells. These cells express negli-
gible levels of cR1 constitutively [27]. Subcon£uent
MCF-7 cells in 24-well culture plates were ¢rst in-
fected with a recombinant vaccinia virus (VTF7ÿ3)
encoding T7 RNA polymerase and then transfected
with pSPORT-cDNA construct in the presence of
Lipofectin [25^27]. Twelve hours post transfection,
the medium was removed by aspiration and the cells
washed once with ice-cold 5 mM K2HPO4-KH2PO4
bu¡er, pH 7.5. 250 Wl of this bu¡er was then added
to the cells and the cells were subjected to a freeze^
thaw procedure once. The lysate was centrifuged at
40 000Ug for 30 min and the membrane pellet was
suspended in the binding bu¡er.
2.4. Treatment with 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide (EDC)
Crude membranes prepared from JAR cells or
MCF-7 cells were treated with varying concentra-
tions of EDC in 5 mM K2HPO4-KH2PO4 bu¡er
(pH 7.5) for 1 h at room temperature. Following
this treatment, the reaction mixture was diluted
with ice-cold bu¡er and centrifuged at 40 000Ug
for 30 min to pellet the membranes. Unreacted
EDC was removed by this procedure. The membrane
pellet was suspended in the same bu¡er and used for
ligand-binding measurements.
2.5. Ligand-binding assay
The membranes were incubated with radiolabeled
c ligands (haloperidol, (+)-pentazocine) in 5 mM
K2HPO4-KH2PO4 bu¡er (pH 7.5) [14,17]. A 3 h in-
cubation was used for all equilibrium binding assays.
Binding was terminated by the addition of ice-cold
binding bu¡er, followed by ¢ltration of the mixture
on a Whatman GF/F glass ¢ber ¢lter presoaked in
0.3% polyethylenimine. The ¢lters were washed
thrice with ice-cold binding bu¡er. Radioactivity as-
sociated with the ¢lters was determined by liquid
scintillation spectrometry.
2.6. Site-directed mutagenesis
The Quick-change site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) was used to intro-
duce point mutations in the C-terminal half of the
human cR1 protein sequence. The procedure was
performed using Pfu DNA polymerase which repli-
cates both plasmid strands with high ¢delity and
without displacing the mutant primers. Two syn-
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thetic oligonucleotide primers (sense and antisense)
speci¢c for the human cR1 cDNA and containing
the desired mutation in the middle were used. Fol-
lowing PCR with the wild type human cR1 cDNA
as the template, the product was digested with DpnI
to digest the parental DNA template, leaving behind
the nicked dsDNA containing the mutation intro-
duced in the primers. The resultant product was
then transformed into Escherichia coli for repair of
the nicks and ampli¢cation. The entire coding region
of the mutant cDNAs was sequenced to con¢rm
the presence of the introduced mutations and the
absence of any unwanted mutations arising from
PCR.
2.7. Analysis of cR1 protein expression
The MCF-7 cells, cultured on chamber slides, were
transfected with wild type or mutant cR1 cDNA
using the vaccinia virus expression technique. After
12 h of transfection, the medium was removed and
the cells were washed with phosphate-bu¡ered saline
(PBS). The cells were ¢xed with ice-cold methanol
for 5 min. The ¢xative was removed and the cells
were permeabilized with 0.1% Triton X-100 for
5 min. The cells were washed with PBS and then
treated with 4% goat serum for 30 min. The cR1-
speci¢c monoclonal antibody [32] was added to the
cells and incubated for 3 h at room temperature and
then overnight at 4‡C. Following the incubation, the
cells were washed with PBS and then incubated over-
night at 4‡C with FITC-coupled anti-mouse IgG
antibody. After the incubation, the cells were
washed, covered with Vectashield, and coverslipped.
Sections were analyzed by laser-scanning confocal
microscopy (Bio-Rad MRC 600 Laser Scanning
Confocal Imaging System).
2.8. In situ hybridization
The brain from CBA adult mice was collected and
immediately frozen in liquid nitrogen. Un¢xed 12 Wm
serial sections were prepared on a cryostat, mounted
on 2% 3-aminopropyltriethoxysilane-coated slides,
air-dried for 10 min, and then stored at 370‡C until
required. In situ hybridization using digoxigenin
UTP-labeled probes was performed on tissue sections
as previously described [35,36]. For the preparation
of the mouse cR1-speci¢c riboprobe, a 0.65 kb frag-
ment of the mouse cR1 cDNA, obtained by the di-
gestion of pSPORT-mouse cR1 cDNA by SalI-
SmaI, was subcloned into pBluescript vector. The
orientation of the cDNA insert in the pBluescript
vector was determined by sequencing. Antisense
and sense riboprobes were synthesized with T7
RNA polymerase or T3 RNA polymerase after line-
arization of the plasmid with appropriate restriction
enzymes. The riboprobes were labeled using a digox-
igenin-labeling kit (Boehringer-Mannheim, Indianap-
olis, IN, USA).
3. Results and discussion
3.1. Expression pattern of cR1 mRNA in the brain
Fig. 1 describes the in situ hybridization data for
the expression of cR1 mRNA in the mouse brain.
The expression of cR1 mRNA is evident throughout
the brain, especially in the cerebral cortex (C), hippo-
campus (H), and cerebellum (CB). Within the hippo-
campus, the cR1 mRNA-speci¢c hybridization sig-
nals are found in cornu ammonis pyramidal neurons
(CA), the granular cells of the dentate gyrus (DG) as
well as interneurons. Within the cerebellum, the sin-
gle layer of Purkinje cell bodies that lie between the
granular cell layer (G) and the molecular layer (ML)
as well as the cell bodies in the deep cerebellar nuclei
(D) are intensely positive for cR1 mRNA. The con-
voluted folia which are supported by the central me-
dulla of white matter (M) does not express cR1. This
expression pattern of cR1 mRNA by in situ hybrid-
ization correlates with the previous ¢ndings on the
expression pattern of cR1-speci¢c ligand binding [5^
8]. McLean and Weber [5] found cR1-speci¢c ligand-
binding sites to be highly concentrated in the Pur-
kinje cell layer of the cerebellum and the pyramidal
cell layer of the hippocampus. Gundlach et al. [6]
have analyzed in greater detail the expression pattern
of cR1 in the hippocampus by ligand binding. Their
results have shown that cR1 is present in pyramidal
neurons rather than in the terminals of input neurons
from the entorhinal cortex and lateral septum. The
high level of expression of cR1 in the cerebellum and
hippocampus suggests a role for this receptor in mo-
tor functions, emotion, and memory.
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3.2. Inhibition of ligand-binding function of human
cR1 by carboxy group-speci¢c chemical
modi¢cation
To determine whether or not the ligand-binding
site of the human cR1 possesses essential anionic
amino acid residues, the JAR cell membranes which
contain the constitutively expressed cR1 and the
MCF-7 cell membranes which contain the heterolo-
gously expressed human cR1 were subjected to
chemical modi¢cation with EDC. This reagent is spe-
ci¢c for the carboxy groups and causes covalent
modi¢cation of the carboxy groups of anionic amino
acid residues (aspartate and glutamate) in proteins.
Following treatment with this reagent, the mem-
branes were used for binding of c ligands (haloper-
idol and (+)-pentazocine). Initial experiments to op-
timize the e¡ect of this reagent employed increasing
concentrations of the reagent. These studies showed
that 1 mM EDC produced the maximal e¡ect (data
not shown). Figs. 2 and 3 describe the inhibition of
c ligand binding to native (JAR cell membranes) and
cloned cR1 (MCF-7 cell membranes) by EDC treat-
ment. Treatment of the JAR cell membranes with
EDC (1 mM) caused 65^70% inhibition of the bind-
ing of (+)-pentazocine and haloperidol (Fig. 2). Sim-
ilarly, MCF-7 cell membranes containing the hetero-
logously expressed human cR1 showed 60^65%
inhibition of the binding of the c ligands as a result
of EDC treatment (Fig. 3). Membranes from MCF-7
cells transfected with the pSPORT vector alone
showed negligible c ligand binding and this binding
was not a¡ected by EDC treatment. This is in agree-
ment with our earlier ¢ndings that MCF-7 cells ex-
Fig. 1. In situ hybridization for analysis of regional distribution pattern of cR1 mRNA in mouse brain. (a) Sagittal section of an
adult mouse brain hybridized with an antisense cR1 probe (C, cortex; H, hippocampus; CB, cerebellum). (b) Higher power image of
cerebral cortex. (c) Higher power image of hippocampus (C, cerebral cortex; CA, cornu ammonis neurons; DG, dentate gyrus). (d)
Higher power image of cerebellum (G, granular layer; ML, molecular layer; M, medulla of white matter; D, deep cerebellar nuclei ;
arrows, Purkinje cell bodies). Use of sense cR1 probe did not yield detectable hybridization signals under identical conditions in any
of the brain regions (data not shown).
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press negligible levels of cR1 [27]. These results dem-
onstrate that the ligand-binding site of human cR1
contains anionic amino acid residues that are essen-
tial for the ligand-binding function.
3.3. Conserved anionic amino acid residues in the
C-terminal half of the c receptor
Human cR1 is a small protein consisting of 223
amino acids. Anionic amino acids constitute approx.
10% of the total amino acids in the protein (15 glu-
tamate residues and six aspartate residues) and each
one of these 21 anionic amino acid residues is con-
served in cR1s derived from di¡erent animal species
(Fig. 4). cR1 is an integral membrane protein and
contains a single putative transmembrane domain
that is located in the region comprising the amino
acid residues 92^113. We have previously identi¢ed
an alternative splice variant of cR1 that lacks exon 3
and has no ability to bind c ligands [17]. The region
deleted in the splice variant consists of the amino
acid residues 119^149. Thus, the putative mem-
brane-spanning domain lies upstream from the re-
gion coded by exon 3. Since the splice variant lacks
the ligand-binding function, we speculated that the
ligand-binding site is present in the C-terminal half
of the protein downstream from the membrane-span-
ning domain in the wild type cR1. This region con-
tains 12 anionic amino acid residues and one or more
of these residues is/are likely to be involved in ligand
binding. The location of the putative transmembrane
Fig. 4. Location of the putative transmembrane domain and
the anionic amino acid residues in the C-terminal half of the
cR1 conserved across the species. gpSigmaR1, guinea pig cR1;
hSigmaR1, human cR1; rSigmaR1, rat cR1; mSigmaR1,
mouse cR1.
Fig. 3. E¡ect of EDC treatment on ligand binding to the
cloned cR1. The human cR1 cDNA was expressed heterolo-
gously in cR1-negative MCF-7 cells. Cells transfected with
pSPORT vector alone were used as negative control. Mem-
branes were prepared from cells transfected with either empty
vector or cR1 cDNA and then treated in the presence or ab-
sence of 1 mM EDC for 1 h. Equilibrium binding of (+)-penta-
zocine (2 nM) and haloperidol (1 nM) was measured in these
membranes. Results are given as percent of binding of respec-
tive ligands in membranes treated in the absence of EDC. This
value was 0.31 þ 0.01 pmol/106 cells for (+)-pentazocine and
2.06 þ 0.51 pmol/106 cells for haloperidol.
Fig. 2. E¡ect of EDC treatment on c ligand binding in JAR
cell membranes. Membranes were treated with or without (con-
trol) 1 mM EDC for 1 h. Control and treated membranes were
used for equilibrium binding of the c ligands (+)-pentazocine
(2 nM) and haloperidol (1 nM). Results are given as percent of
binding of respective ligands in control membranes. The control
value was 0.30 þ 0.01 pmol/mg of protein for (+)-pentazocine
and 2.10 þ 0.09 pmol/mg of protein for haloperidol.
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domain and the conserved anionic amino acid resi-
dues in the C-terminal half of the cR1 protein are
shown in Fig. 4.
3.4. Ligand-binding function and protein expression of
the mutants
To identify the anionic amino acid residues essen-
tial for the ligand-binding function, we mutated each
of the 12 anionic amino acid residues in the C-termi-
nal half of the cR1 and assessed the in£uence of the
mutations on the ligand-binding function. In each
case, the anionic amino acid residue was converted
to the neutral amino acid glycine. Table 1 describes
the ligand-binding function of the mutants and the
wild type cR1. The binding activity of most of these
mutants varied in the range of 75^120% compared to
the wild type cR1. However, two of the mutants
(D126G and E172G) showed very little ligand bind-
ing (6 10% of the wild type cR1 activity). These
data indicated that D126 and E172 are involved in
the binding of the c ligands to cR1, but an alterna-
tive explanation may be that the mutation of these
two amino acids decreases the stability of the protein
and that the observed loss of ligand-binding activity
is due to enhanced degradation of the protein. There-
fore, we investigated the protein expression of the
two mutants using a cR1-speci¢c monoclonal anti-
body (Fig. 5). We expressed the wild type and the
two mutant cR1s in cR1-negative MCF-7 cells het-
erologously. Cells transfected with vector alone
served as the negative control. As expected, there
was no immunodetectable protein signal in MCF-7
cells transfected with vector alone. However, an im-
munopositive signal was detectable in the nuclear
envelope in cells expressing the wild type cR1.
More importantly, the subcellular localization as
well as the intensity of the immunopositive signal
were comparable in cells expressing the wild type
cR1 and in cells expressing either of the two mutant
cR1s. These results show that the expression of cR1
is not altered as a consequence of the mutations
D126G and E172G. The nuclear envelope localiza-
tion of the heterologously expressed human cR1 in
MCF-7 cells agrees with the data on the localization
of constitutively expressed cR1 in human immune
cells [32]. Taken collectively, these data demonstrate
the obligatory nature of D126 and E172 for the li-
gand-binding function of cR1.
In summary, the present studies provide important
Fig. 5. Immunodetection of the expression of wild type and
mutant cR1s. cR1-negative MCF-7 cells were transfected with
vector alone (pSPORT), wild type cR1 cDNA (WT), D126G
mutant cR1 cDNA (D126G) or E172G mutant cR1 cDNA
(E172G). Twelve hours after transfection, the expressed cR1
proteins were detected with a cR1-speci¢c monoclonal antibody
and a FITC-coupled secondary antibody.
Table 1
Ligand-binding activity of the wild type and mutant cR1s
Wild type/mutant cR1 [3H]Haloperidol binding
pmol/106 cells %
Wild type 4.24 þ 0.47 100
E123G 4.55 þ 0.58 107
D126G 0.37 þ 0.02 9
E138G 3.25 þ 0.46 77
E144G 3.15 þ 0.34 74
E150G 3.32 þ 0.20 78
E158G 3.28 þ 0.45 77
E163G 4.31 þ 0.14 102
E172G 0.14 þ 0.04 3
D188G 5.13 þ 0.56 121
D195G 4.05 þ 0.40 96
E213G 4.62 þ 0.22 109
E222G 3.24 þ 0.29 76
The wild type and mutant cR1s were expressed heterologously
in MCF-7 cells using the vaccinia virus expression technique.
Crude membranes from these cells were used for equilibrium
binding of [3H]haloperidol. Concentration of the ligand during
the binding assay was 3 nM.
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information in two areas of cR1 biology, namely the
expression pattern and the structure^function rela-
tionship. These studies identify for the ¢rst time the
speci¢c brain areas that express cR1 mRNA. The
present data on the expression pattern of cR1
mRNA by in situ hybridization correlate very well
with the previous ¢ndings on the distribution of
cR1-speci¢c ligand-binding sites in the brain [5^8].
The receptor is expressed abundantly in the hippo-
campus and in the Purkinje cells of the cerebellum.
Since these regions are known to be involved in im-
portant brain functions relating to memory, emotion,
and motor activity, we speculate that cR1 may have
a physiological role in the modulation of these crit-
ical brain functions. A number of studies have shown
that cR1-speci¢c ligands are e¡ective as neuroprotec-
tive and anti-amnesic agents [37^42], and the wide-
spread expression of the receptor in the brain, par-
ticularly in the hippocampus and cerebellum, may
have relevance to the observed therapeutic e¡ects
of cR1-speci¢c ligands.
cR1 is expressed not only in the brain but also in
several other tissues. In addition to the previously
stated therapeutic role in neuroprotection and amelio-
ration of memory defects, cR1-speci¢c ligands have
also been shown to be e¡ective as anti-in£ammatory
agents [16,32,43,44] and in the treatment of ocular
hypertension associated with glaucoma [45]. These
¢ndings suggest that cR1 is a potential therapeutic
target in the treatment of a multitude of clinical con-
ditions. The design of highly selective cR1 ligands
with no or little a⁄nity towards other receptors is
necessary to ensure that cR1 is the speci¢c target for
these potential therapeutic agents. The design of such
selective ligands will require detailed information on
the chemical nature of the ligand-binding domain of
the receptor. The present studies show for the ¢rst
time that anionic amino acid residues in the receptor
are critical for ligand binding. In addition, these
studies have identi¢ed two speci¢c anionic amino
acid residues that play an essential role in the ligand
binding, suggesting that these residues are located
most likely in the ligand-binding domain. This in-
formation on the molecular nature of the ligand-
binding region of the receptor is potentially useful
in the future design of cR1-selective therapeutic
agents.
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